Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment.

ABSTRACT: The optimal treatment sequence in non-small cell lung cancer harboring class I BRAF mutations and atypical BRAF variants remains unclear. To better characterize therapeutic strategy, we retrospectively evaluated a multi-institutional cohort of BRAF-mutant NSCLC patients (n = 97) and an independent clinico-genomic database (n = 342), performed structural modeling, and conducted chemical screens of BRAF-mutant cell lines. Patients with class I BRAF mutation treated with BRAF-MEK inhibitors at any line of therapy had significantly greater median overall survival compared to those who did not receive BRAF-MEK inhibitors (40 vs 10 months, Log-rank p = 0.043). There, however, was no significant survival difference between patients treated with immune checkpoint inhibitors versus those not treate

SUBMITTER: Lu K 

PROVIDER: S-EPMC12568928 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature